Pfizer Reports Q1 2026 Revenues of $14.5B with 7% Operational Growth Excluding COVID-19 Products, Reaffirms Full-Year Guidance
Pfizer Inc. (NYSE: PFE) reported first quarter 2026 financial results on May 5, 2026, with...
Pfizer
3SBio Reports 94% Revenue Surge to $2.58B in 2025 Driven by $6B Pfizer PD-1/VEGF Bispecific Antibody Deal
3SBio Inc. (HKG: 1530) reported 2025 financial results with revenues soaring 94.3% year-over-year (YOY) to...
Pfizer Extends VYNDAMAX Patent Protection to 2031 Through Generic Settlements
Pfizer Inc. (NYSE: PFE) announced settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals,...
Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant
Bristol-Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE) announced a landmark collaboration with Mark Cuban...
FDA Grants Priority Review to Merck, Astellas, and Pfizer’s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer
Merck & Co. (MSD, NYSE: MRK), Astellas Pharma (TYO: 4503), and Pfizer Inc. (NYSE: PFE)...
China’s NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program
The National Healthcare Security Administration (NHSA) has published the inaugural list of 31 innovative drugs...
Pfizer Reports Positive TALAPRO-3 Results – TALZENNA/XTANDI Combo Hits Primary Endpoint in HRR-Mutated Prostate Cancer
Pfizer Inc. (NYSE: PFE) announced positive topline results from the Phase 3 TALAPRO-3 study, demonstrating...
Pfizer Reports Positive FOURLIGHT-1 Results for Atirmociclib – CDK4 Inhibitor Shows PFS Benefit in Post-CDK4/6 Breast Cancer
Pfizer Inc. (NYSE: PFE) announced positive topline results from the Phase II FOURLIGHT-1 study, demonstrating...
Pfizer’s Tilrekimig Hits Phase 2 Primary Endpoint – IL-4/IL-13/TSLP Trispecific Shows 52% EASI-75 Response in Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) announced positive topline results from a Phase 2 study of tilrekimig...
Sciwind’s Ecnoglutide Wins NMPA Approval for Weight Loss – World’s First cAMP-Biased GLP-1 Agonist Targets China Obesity Market
Sciwind Biosciences announced that Ecnoglutide injection (Xianweiying), the world’s first cAMP-biased GLP-1 receptor agonist, has...
Pfizer Partners with Sciwind Biosciences for Ecnoglutide China Rights – $495M Deal Marks Metabolic Market Entry
Pfizer Inc. (NYSE: PFE) has entered into an exclusive commercialization agreement with Sciwind Biosciences Co., Ltd....
Pfizer’s Cresemba Wins NMPA Pediatric Approval for Invasive Fungal Infections
Pfizer Inc. (NYSE: PFE) announced that the National Medical Products Administration (NMPA) has approved an indication...
Pfizer’s Hympavzi Wins FDA Priority Review for Pediatric Hemophilia Expansion
Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted...
Pfizer Launches Migraine Management Zone at China Pharmacy
Pfizer Inc. (NYSE: PFE) in collaboration with GuoDa Drugstore Co., Ltd. (part of Sinopharm) this week...
ASCP Launches $250K Grants for mCRC Biomarker Testing with Pfizer, ASCO
The American Society for Clinical Pathology (ASCP), in collaboration with Pfizer (NYSE: PFE) and with participation...
Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal
Novavax, Inc. (NASDAQ: NVAX) entered into a license agreement with Pfizer Inc. for non‑exclusive rights to...
Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus
Shionogi Co., Ltd announced it will invest USD 2.1 billion to increase its stake in ViiV Healthcare...
Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer
Pfizer Inc. (NYSE: PFE) announced that Cohort 3 of the pivotal Phase 3 BREAKWATER trial met its primary...
Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push
Merck Sharp & Dohme Inc. (MSD, NYSE: MRK) is reportedly in advanced negotiations to acquire Revolution Medicines...
Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal
Pfizer Inc. (NYSE: PFE) and Cartography Biosciences, Inc. announced a strategic collaboration to discover tumor-selective...